VIENNA (Reuters) - Drugmaker Novartis aims to dispose of a 13.5 billion Swiss franc ($13.8 billion) stake in its local rival Roche and has already hired banks to support the selling process, a Swiss paper reported on Sunday.
The world's biggest prescription drugmaker started building up the stake - worth 33 percent of Roche's voting shares - as a basis for a possible merger more than a decade ago, but the plan never materialised.
Novartis plans to sell the stake in a so-called order book process, having banks collect purchase offers within a predefined price range from selected investors, weekly Sonntagszeitung said, citing board and banking sources.
A Novartis spokesman declined to comment on the report.
($1 = 0.8909 euros)
($1 = 0.9781 Swiss francs)
(Reporting by Kirsti Knolle; Editing by Alison Williams)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
